None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relias, LLC and National Council for Mental Wellbeing guarantee this educational conference is free from bias.
Patients' experiences, perspectives and needs must be incorporated when developing and evaluating new medications. We will discuss examples of capturing the patient perspective with a focus on patients living with serious mental illness. First, we will review the methodologies and results of studies using qualitative and quantitative research methods, which shed light on the burden of illness and unmet treatment needs among patients living with schizophrenia and bipolar I disorder. Second, we will review the methodology of a series of exit interviews from a clinical trial that sought to understand treatment benefit, burden and satisfaction among patients living with schizophrenia. Third, we will describe examples of how patients and patient advocacy groups can be included throughout the development of new medications.
Analyze findings of recent studies of patient voice in clinical decision-making.
Describe patient preferences when considering tolerance of treatment and efficacy.
Explore best practices for incorporating patient voice in planning of treatment.